Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis-Reference-Cited by-同舟云学术

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis

Published:2014-03-04 Issue:4 Volume:29 Page:1017-1025
ISSN:0885-7490
Container-title:Metabolic Brain Disease
language:en
Short-container-title:Metab Brain Dis

Author:

Ahluwalia Vishwadeep,Wade James B.,Heuman Douglas M.,Hammeke Thomas A.,Sanyal Arun J.,Sterling Richard K.,Stravitz R. Todd,Luketic Velimir,Siddiqui Mohammad S.,Puri Puneet,Fuchs Michael,Lennon Micheal J.,Kraft Kenneth A.,Gilles HoChong,White Melanie B.,Noble Nicole A.,Bajaj Jasmohan S.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology,Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s11011-014-9507-6.pdf

Reference39 articles.

1. Amodio P, Montagnese S, Gatta A, Morgan MY (2004) Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 19(3–4):253–267

2. Bajaj JS, Wade JB, Sanyal AJ (2009) Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 50(6):2014–2021. doi: 10.1002/hep.23216

3. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140(2):478–487. doi: 10.1053/j.gastro.2010.08.061

4. Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM, Kettenmann B, Schubert CM, Sikaroodi M, Heuman DM, Crossey MM, Bell DE, Hylemon PB, Fatouros PP, Taylor-Robinson SD (2012) A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis 27(2):205–215. doi: 10.1007/s11011-012-9303-0

5. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8(4):e60042. doi: 10.1371/journal.pone.0060042

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of rifaximin in liver diseases;Biomedicine & Pharmacotherapy;2024-09

2. Influence of human gut microbiome on the healthy and the neurodegenerative aging;Experimental Gerontology;2024-09

3. Mendelian randomization study reveals causal effects of specific gut microbiota on the risk of interstitial cystitis/bladder pain syndrome (IC/BPS);Scientific Reports;2024-08-08

4. Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study;World Journal of Hepatology;2024-05-27

5. Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity;Journal of Translational Medicine;2024-01-12